UK
Dr Ben Bray
He/HimI am a Partner and Evidence Generation Lead in the Health Analytics team, as well as a medical doctor and epidemiologist with a clinical background in nephrology and public health.
I have more than 10 years’ experience in academia and industry designing and executing scientific studies using real world health data, and developing advanced analytics solutions to support healthcare providers and life sciences companies.
My previous roles have included Clinical Lead (Stroke) for the National Cardiovascular Intelligence Network of Public Health England, and Clinical Advisor to NHS England and NHS Kidney Care. I am Honorary Senior Clinical Lecturer at King’s College London, where I work on research into machine learning analytics using large health databases. I’m an author on more than 40 peer reviewed publications and I sit on the editorial board of the Drug Safety journal.
I have completed a BSc in Neuroscience, MBChB (Medicine) and MD (Epidemiology) at the University of Edinburgh, and a Masters in Public Health at the London School of Hygiene and Tropical Medicine. I am a Member of the Royal College of Physicians and Faculty of Public Health, and Fellow of the Faculty of Clinical Informatics.
LCP are a professional organization, which understands the clients' needs and demonstrates the depth and creativity of its experience in the solutions it provides.
LCP Client
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
